


Supplementary 1. Gating strategy for intracellular cytokine staining (ICS).



Gating Strategy







Output in percentage :



1. Non Debris – Cell (Lymphocytes)
2. Single Cells
3. % CD3 (+) & Viable % T Lymphocytes
4. % CD3+/CD154+/IFN+ (Q2)
5. % CD3+/IFN+
6. % CD3+/CD154+/TNF+ (Q6)
7. % CD3+/TNF+
8. % CD3+/CD4+
9. % CD3+/CD4+/CD154+/IFN+ (Q2)
10. CD3+/CD4+/IFN+
11. CD3+/CD4+/CD154+/TNF+ (Q6)
12. CD3+/CD4+/TNF+



13. % CD3+/CD8+
14. % CD3+/CD8+/CD154+/IFN+
15. % CD3+/CD8+/IFN+
16. % CD3+/CD8+/CD154+/TNF+
17. % CD3+/CD8+/TNF+



1	Non Debris – Cell (Lymphocytes)	 <p>01-09-2022_AIM P06.fcs Ungated 306477</p>
2	Single Cells	 <p>01-09-2022_AIM P06.fcs Lymphocytes 216353</p>



<p>3.</p>	<p>% CD3 (+) & Viable</p> <p>Marker : CD3 : APC Viable : Pacific Blue</p>	 <p>01-09-2022_AIM P06.fcs Single Cells 214887</p>
<p>4</p>	<p>% CD3+/CD154+/IFN+ (Q2)</p> <p>Marker : CD154 : APC Cy.7 IFN gamma : PE</p> <p>Graphic type : Quadrant dot plot</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>



<p>5</p>	<p>% CD3+/IFN+</p> <p>Marker : IFN Gamma : PE</p> <p>Graphic type : Histogram</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>
<p>6.</p>	<p>% CD3+/CD154+/TNF+ (Q6)</p> <p>Marker : TNF : PE Cy.7</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>

7.	<p>% CD3+/TNF+</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>
8.	<p>% CD3+/CD4+</p> <p>Marker : CD4 : FITC</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>

9.	% CD3+/CD4+/CD154+/IFN+ (Q2)	 <p>01-09-2022_AIM P06.fcs CD4+ 75158</p>
10	CD3+/CD4+/IFN+	 <p>01-09-2022_AIM P06.fcs CD4+ 75158</p>


11	CD3+/CD4+/CD154+/TNF+ (Q6)	 <p>01-09-2022_AIM P06.fcs CD4+ 75158</p>
12	CD3+/CD4+/TNF+	 <p>01-09-2022_AIM P06.fcs CD4+ 75158</p>

13	<p>% CD3+/CD8+</p> <p>Marker :</p> <p>CD8 : Amcyan</p>	 <p>01-09-2022_AIM P06.fcs CD3+ Viable 137083</p>
14	<p>% CD3+/CD8+/CD154+/IFN+</p>	 <p>01-09-2022_AIM P06.fcs CD8+ 34030</p>

15	% CD3+/CD8+/IFN+	 <p>01-09-2022_AIM P06.fcs CD8+ 34030</p>
16	% CD3+/CD8+/CD154+/TNF+	 <p>01-09-2022_AIM P06.fcs CD8+ 34030</p>

17

% CD3+/CD8+/TNF+



01-09-2022_AIM P06.fcs
CD8+
34030